VEGF-C (human, recombinant)

VEGF-C (human, recombinant)
Item number Size Datasheet Manual SDS Delivery time Quantity Price
Cay32054-5 5 µg -

6 - 10 business days*

86.00€
Cay32054-100 100 µg -

6 - 10 business days*

427.00€
Cay32054-1 1 mg -

6 - 10 business days*

2,221.00€
 
VEGF-C is a member of the PDGF/VEGF family of growth factors that promotes lymphangiogenesis.... more
Product information "VEGF-C (human, recombinant)"
VEGF-C is a member of the PDGF/VEGF family of growth factors that promotes lymphangiogenesis. VEGF-C exists as a secreted homodimer composed of a central VEGF homology domain that contains the receptor binding region and is flanked by N- and C-terminal propeptides, which are proteolytically cleaved by furin and ADAMTS3 or plasmin to generate the mature, active protein. VEGF-C is produced by macrophages, fibroblasts, smooth muscle cells, and tumor cells. VEGFC expression is upregulated by stimulation with IL-1beta, TNF-alpha (Cay-32020, Cay-32069), PDGF, TGF-beta, or EGF (Cay-32057, Cay-32025) and downregulated by dexamethasone (Cay-11015). Binding of VEGF-C to its receptors, VEGFR2 and VEGFR3, which are expressed by endothelial cells, stimulates the migration, proliferation, and survival of endothelial cells and increases vascular permeability. VEGF-C induces angiogenesis in chick embryo chorioallantoic membranes and stimulates proliferation and migration of porcine aortic endothelial cells in vitro. Genome-wide deletion of Vegfc in mice induces embryonic edema and defects in lymphatic vascular development and is perinatal lethal. Increased VEGF-C tumor levels are positively correlated with poor prognosis, decreased overall survival, and resistance to hormone therapy in patients with breast cancer. VEGFC SNPs have been found in patients with non-small cell lung cancer (NSCLC), as well as colorectal or prostate cancer. Cayman's VEGF-C (human, recombinant) protein can be used for binding and cell-based assay applications. This protein consists of 136 amino acids, has a calculated molecular weight of 15.5 kDa, and a predicted N-terminus of Thr103 after signal peptide cleavage. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is approximately 22 to 24 kDa due to glycosylation.Synonyms: FLT4-L, FLT4 Ligand, Vascular Endothelial Growth Factor C. Purity: >95% estimated by SDS-PAGE. Endotoxin Testing: <1.0 EU/µg, determined by the LAL endotoxin assay. Source: Active recombinant human C-terminal His-tagged VEGF-C expressed in HEK293 cells. Amino Acids: 103-227. MW: 15.5 kDa. Formulation: (Request formulation change), Lyophilized from sterile PBS, pH 7.4, with 5% trehalose, 5% mannitol, and 0.01% Tween 80. UniProt Accession #: P49767.
Keywords: VRP, VRP, VEGFC, VEGF-C, Flt4-L, VEGF-C, Flt4-L, Flt4 ligand, Flt4 ligand, Vascular endothelial growth factor C, Vascular endothelial growth factor C, Vascular endothelial growth factor-related protein, Vascular endothelial growth factor-related protein
Supplier: Cayman Chemical
Supplier-Nr: 32054

Properties

Application: ELISA
Conjugate: No
Purity: >95% estimated by SDS-PAGE
Format: Lyophilized

Handling & Safety

Storage: -80°C
Shipping: -80°C (International: -80°C)
Caution
Our products are for laboratory research use only: Not for administration to humans!
You will get a certificate here
or to request a certificate of analysis.
Read, write and discuss reviews... more
Customer review for "VEGF-C (human, recombinant)"
Write a review
or to review a product.
Viewed